GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genoptix Inc (DELISTED:GXDX) » Definitions » PE Ratio (TTM)

Genoptix (Genoptix) PE Ratio (TTM) : N/A (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Genoptix PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), Genoptix's share price is $0.00. Genoptix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00. Therefore, Genoptix's PE Ratio (TTM) for today is N/A.


The historical rank and industry rank for Genoptix's PE Ratio (TTM) or its related term are showing as below:

GXDX' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



GXDX's PE Ratio (TTM) is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 31.24 vs GXDX: At Loss

Genoptix's Earnings per Share (Diluted) for the three months ended in Sep. 2010 was $0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00.

As of today (2024-04-26), Genoptix's share price is $0.00. Genoptix's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00. Therefore, Genoptix's PE Ratio without NRI for today is N/A.

Genoptix's EPS without NRI for the three months ended in Sep. 2010 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00.

Genoptix's EPS (Basic) for the three months ended in Sep. 2010 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00.


Genoptix PE Ratio (TTM) Historical Data

The historical data trend for Genoptix's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genoptix PE Ratio (TTM) Chart

Genoptix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
PE Ratio (TTM)
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Genoptix Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Genoptix's PE Ratio (TTM)

For the Diagnostics & Research subindustry, Genoptix's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genoptix's PE Ratio (TTM) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genoptix's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Genoptix's PE Ratio (TTM) falls into.



Genoptix PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Genoptix's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Genoptix's Share Price of today is $0.00.
Genoptix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Genoptix  (DELISTED:GXDX) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Genoptix PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Genoptix's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genoptix (Genoptix) Business Description

Traded in Other Exchanges
N/A
Address
Website
Genoptix, Inc. incorporated in Delaware in January 1999. It is a specialized laboratory service provider, which is focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists, or hem/oncs. Its group of hematopathologists utilizes diagnostic technologies to provide a differentiated, specialized and integrated assessment of a patient's condition, aiding hem/oncs in making vital decisions concerning the treatment of malignancies of the blood and bone marrow, and other forms of cancer. The company's key service offerings, COMPASS and CHART, are designed to meet the specific needs of community-based hem/oncs. Its COMPASS service offering includes the determination by its hempaths of the appropriate diagnostic tests to be conducted and the performance of these tests. It then evaluate, synthesize and summarize the results into an easy to read comprehensive report, and its hempaths are available to interpret these results jointly with the hem/onc, giving them the benefit of its expertise and analytical experience. The company's CHART service offering combines multiple COMPASS assessments and analyses of disease progression after intervening clinical action, providing the hem/onc with a valuable diagnostic tool to track both a patient's disease and response to the hem/onc's prescribed treatment regimen over time. The Company believes its sales and marketing approach distinguishes it from its competitors. Most of its sales representatives have a four-year Bachelor of Science or Arts degree, primarily in the biological sciences, and a three-to five-year history selling diagnostic services or niche pharmaceuticals directly to hem/oncs. As a specialized diagnostic service provider, it relies extensively on its quality of service to attract and retain community-based hem/oncs and other healthcare professionals as its customers. As a diagnostic service provider, the Company is required to hold certain federal, state and local licenses, certifications and permits to conduct its business.

Genoptix (Genoptix) Headlines

No Headlines